APO Research
Talk to an analyst

APO RESEARCH · REPORT

Friedreich Ataxia Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Friedreich Ataxia Drug Market Outlook and Growth Opportunities 2026

19 December 2025196 pages

Choose your research edition.

Industry ResearchFriedreich Ataxia Drug Industry Research Report 2026138 pages · $2,950 USDIndustry Growth & TrendsGlobal Friedreich Ataxia Drug Industry Growth and Trends Forecast to 2032117 pages · $3,450 USDMarket StructureGlobal Friedreich Ataxia Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Friedreich Ataxia Drug Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Friedreich Ataxia Drug Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Friedreich Ataxia Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Friedreich Ataxia Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Friedreich Ataxia Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Friedreich Ataxia Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Friedreich Ataxia Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Friedreich Ataxia Drug market include Takeda, Pfizer Inc, Voyager Therapeutics Inc, STATegics Inc, Retrotope Inc, Reata Pharmaceuticals Inc, RaNA Therapeutics Inc, ProQR Therapeutics NV and Ixchel Pharma LLC, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Friedreich Ataxia Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Friedreich Ataxia Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Friedreich Ataxia Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Friedreich Ataxia Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Friedreich Ataxia Drug Segment by Company

Takeda

Pfizer Inc

Voyager Therapeutics Inc

STATegics Inc

Retrotope Inc

Reata Pharmaceuticals Inc

RaNA Therapeutics Inc

ProQR Therapeutics NV

Ixchel Pharma LLC

Forward Pharma A/S

Catabasis Pharmaceuticals, Inc.

Cardero Therapeutics Inc

Biovista Inc.

BioMarin Pharmaceutical Inc.

Adverum Biotechnologies Inc

Friedreich Ataxia Drug Segment by Type

BVA-202

BHV-4157

AGIL-FA

ADVM-063

Others

Friedreich Ataxia Drug Segment by Application

Clinic

Hospital

Others

Friedreich Ataxia Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Friedreich Ataxia Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Friedreich Ataxia Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Friedreich Ataxia Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Friedreich Ataxia Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Friedreich Ataxia Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Friedreich Ataxia Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Friedreich Ataxia Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Friedreich Ataxia Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Friedreich Ataxia Drug industry.

Chapter 3: Detailed analysis of Friedreich Ataxia Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Friedreich Ataxia Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Friedreich Ataxia Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Friedreich Ataxia Drug Industry Trends Table 2. Friedreich Ataxia Drug Industry Drivers Table 3. Friedreich Ataxia Drug Industry Opportunities and Challenges Table 4. Friedreich Ataxia Drug Industry Restraints Table 5. Global Friedreich Ataxia Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Friedreich Ataxia Drug Revenue Share by Company (2021-2026) Table 7. Global Friedreich Ataxia Drug Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Friedreich Ataxia Drug Sales Volume Share by Company (2021-2026) Table 9. Global Friedreich Ataxia Drug Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Friedreich Ataxia Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Friedreich Ataxia Drug Key Company Manufacturing Base & Headquarters Table 12. Global Friedreich Ataxia Drug Company, Product Type & Application Table 13. Global Friedreich Ataxia Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Friedreich Ataxia Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of BVA-202 Table 18. Significant Companies of BHV-4157 Table 19. Significant Companies of AGIL-FA Table 20. Significant Companies of ADVM-063 Table 21. Significant Companies of Others Table 22. Global Friedreich Ataxia Drug Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global Friedreich Ataxia Drug Sales Volume by Type (2021-2026) & (K Units) Table 24. Global Friedreich Ataxia Drug Sales Volume by Type (2027-2032) & (K Units) Table 25. Global Friedreich Ataxia Drug Sales Volume Share by Type (2021-2026) Table 26. Global Friedreich Ataxia Drug Sales Volume Share by Type (2027-2032) Table 27. Global Friedreich Ataxia Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Friedreich Ataxia Drug Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Friedreich Ataxia Drug Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Friedreich Ataxia Drug Sales Value Share by Type (2021-2026) Table 31. Global Friedreich Ataxia Drug Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Clinic Table 33. Significant Companies of Hospital Table 34. Significant Companies of Others Table 35. Global Friedreich Ataxia Drug Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Friedreich Ataxia Drug Sales Volume by Application (2021-2026) & (K Units) Table 37. Global Friedreich Ataxia Drug Sales Volume by Application (2027-2032) & (K Units) Table 38. Global Friedreich Ataxia Drug Sales Volume Share by Application (2021-2026) Table 39. Global Friedreich Ataxia Drug Sales Volume Share by Application (2027-2032) Table 40. Global Friedreich Ataxia Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Friedreich Ataxia Drug Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Friedreich Ataxia Drug Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Friedreich Ataxia Drug Sales Value Share by Application (2021-2026) Table 44. Global Friedreich Ataxia Drug Sales Value Share by Application (2027-2032) Table 45. Global Friedreich Ataxia Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global Friedreich Ataxia Drug Sales by Region (2021-2026) & (K Units) Table 47. Global Friedreich Ataxia Drug Sales Market Share by Region (2021-2026) Table 48. Global Friedreich Ataxia Drug Sales by Region (2027-2032) & (K Units) Table 49. Global Friedreich Ataxia Drug Sales Market Share by Region (2027-2032) Table 50. Global Friedreich Ataxia Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Friedreich Ataxia Drug Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Friedreich Ataxia Drug Sales Value Share by Region (2021-2026) Table 53. Global Friedreich Ataxia Drug Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Friedreich Ataxia Drug Sales Value Share by Region (2027-2032) Table 55. Global Friedreich Ataxia Drug Market Average Price (US$/Unit) by Region (2021-2026) Table 56. Global Friedreich Ataxia Drug Market Average Price (US$/Unit) by Region (2027-2032) Table 57. Global Friedreich Ataxia Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Global Friedreich Ataxia Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Friedreich Ataxia Drug Sales by Country (2021-2026) & (K Units) Table 60. Global Friedreich Ataxia Drug Sales Market Share by Country (2021-2026) Table 61. Global Friedreich Ataxia Drug Sales by Country (2027-2032) & (K Units) Table 62. Global Friedreich Ataxia Drug Sales Market Share by Country (2027-2032) Table 63. Global Friedreich Ataxia Drug Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Friedreich Ataxia Drug Sales Value Market Share by Country (2021-2026) Table 65. Global Friedreich Ataxia Drug Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Friedreich Ataxia Drug Sales Value Market Share by Country (2027-2032) Table 67. Takeda Company Information Table 68. Takeda Business Overview Table 69. Takeda Friedreich Ataxia Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. Takeda Friedreich Ataxia Drug Product Portfolio Table 71. Takeda Recent Development Table 72. Pfizer Inc Company Information Table 73. Pfizer Inc Business Overview Table 74. Pfizer Inc Friedreich Ataxia Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Pfizer Inc Friedreich Ataxia Drug Product Portfolio Table 76. Pfizer Inc Recent Development Table 77. Voyager Therapeutics Inc Company Information Table 78. Voyager Therapeutics Inc Business Overview Table 79. Voyager Therapeutics Inc Friedreich Ataxia Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Voyager Therapeutics Inc Friedreich Ataxia Drug Product Portfolio Table 81. Voyager Therapeutics Inc Recent Development Table 82. STATegics Inc Company Information Table 83. STATegics Inc Business Overview Table 84. STATegics Inc Friedreich Ataxia Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. STATegics Inc Friedreich Ataxia Drug Product Portfolio Table 86. STATegics Inc Recent Development Table 87. Retrotope Inc Company Information Table 88. Retrotope Inc Business Overview Table 89. Retrotope Inc Friedreich Ataxia Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Retrotope Inc Friedreich Ataxia Drug Product Portfolio Table 91. Retrotope Inc Recent Development Table 92. Reata Pharmaceuticals Inc Company Information Table 93. Reata Pharmaceuticals Inc Business Overview Table 94. Reata Pharmaceuticals Inc Friedreich Ataxia Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Reata Pharmaceuticals Inc Friedreich Ataxia Drug Product Portfolio Table 96. Reata Pharmaceuticals Inc Recent Development Table 97. RaNA Therapeutics Inc Company Information Table 98. RaNA Therapeutics Inc Business Overview Table 99. RaNA Therapeutics Inc Friedreich Ataxia Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. RaNA Therapeutics Inc Friedreich Ataxia Drug Product Portfolio Table 101. RaNA Therapeutics Inc Recent Development Table 102. ProQR Therapeutics NV Company Information Table 103. ProQR Therapeutics NV Business Overview Table 104. ProQR Therapeutics NV Friedreich Ataxia Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. ProQR Therapeutics NV Friedreich Ataxia Drug Product Portfolio Table 106. ProQR Therapeutics NV Recent Development Table 107. Ixchel Pharma LLC Company Information Table 108. Ixchel Pharma LLC Business Overview Table 109. Ixchel Pharma LLC Friedreich Ataxia Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Ixchel Pharma LLC Friedreich Ataxia Drug Product Portfolio Table 111. Ixchel Pharma LLC Recent Development Table 112. Forward Pharma A/S Company Information Table 113. Forward Pharma A/S Business Overview Table 114. Forward Pharma A/S Friedreich Ataxia Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Forward Pharma A/S Friedreich Ataxia Drug Product Portfolio Table 116. Forward Pharma A/S Recent Development Table 117. Catabasis Pharmaceuticals, Inc. Company Information Table 118. Catabasis Pharmaceuticals, Inc. Business Overview Table 119. Catabasis Pharmaceuticals, Inc. Friedreich Ataxia Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Catabasis Pharmaceuticals, Inc. Friedreich Ataxia Drug Product Portfolio Table 121. Catabasis Pharmaceuticals, Inc. Recent Development Table 122. Cardero Therapeutics Inc Company Information Table 123. Cardero Therapeutics Inc Business Overview Table 124. Cardero Therapeutics Inc Friedreich Ataxia Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. Cardero Therapeutics Inc Friedreich Ataxia Drug Product Portfolio Table 126. Cardero Therapeutics Inc Recent Development Table 127. Biovista Inc. Company Information Table 128. Biovista Inc. Business Overview Table 129. Biovista Inc. Friedreich Ataxia Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 130. Biovista Inc. Friedreich Ataxia Drug Product Portfolio Table 131. Biovista Inc. Recent Development Table 132. BioMarin Pharmaceutical Inc. Company Information Table 133. BioMarin Pharmaceutical Inc. Business Overview Table 134. BioMarin Pharmaceutical Inc. Friedreich Ataxia Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 135. BioMarin Pharmaceutical Inc. Friedreich Ataxia Drug Product Portfolio Table 136. BioMarin Pharmaceutical Inc. Recent Development Table 137. Adverum Biotechnologies Inc Company Information Table 138. Adverum Biotechnologies Inc Business Overview Table 139. Adverum Biotechnologies Inc Friedreich Ataxia Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 140. Adverum Biotechnologies Inc Friedreich Ataxia Drug Product Portfolio Table 141. Adverum Biotechnologies Inc Recent Development Table 142. Key Raw Materials Table 143. Raw Materials Key Suppliers Table 144. Friedreich Ataxia Drug Distributors List Table 145. Friedreich Ataxia Drug Customers List Table 146. Research Programs/Design for This Report Table 147. Authors List of This Report Table 148. Secondary Sources Table 149. Primary Sources List of Figures Figure 1. Friedreich Ataxia Drug Product Image Figure 2. Global Friedreich Ataxia Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Friedreich Ataxia Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Friedreich Ataxia Drug Sales (2021-2032) & (K Units) Figure 5. Global Friedreich Ataxia Drug Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Friedreich Ataxia Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. BVA-202 Image Figure 10. BHV-4157 Image Figure 11. AGIL-FA Image Figure 12. ADVM-063 Image Figure 13. Others Image Figure 14. Global Friedreich Ataxia Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Friedreich Ataxia Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Friedreich Ataxia Drug Sales Volume Share by Type (2021-2032) Figure 17. Global Friedreich Ataxia Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Friedreich Ataxia Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Friedreich Ataxia Drug Sales Value Share by Type (2021-2032) Figure 20. Clinic Image Figure 21. Hospital Image Figure 22. Others Image Figure 23. Global Friedreich Ataxia Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Friedreich Ataxia Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Friedreich Ataxia Drug Sales Volume Share by Application (2021-2032) Figure 26. Global Friedreich Ataxia Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Friedreich Ataxia Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Friedreich Ataxia Drug Sales Value Share by Application (2021-2032) Figure 29. Global Friedreich Ataxia Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 30. Global Friedreich Ataxia Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Friedreich Ataxia Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Friedreich Ataxia Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Friedreich Ataxia Drug Sales Value (2021-2032) & (US$ Million) Figure 34. North America Friedreich Ataxia Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Friedreich Ataxia Drug Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Friedreich Ataxia Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Friedreich Ataxia Drug Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Friedreich Ataxia Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Friedreich Ataxia Drug Sales Value (2021-2032) & (US$ Million) Figure 40. South America Friedreich Ataxia Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Friedreich Ataxia Drug Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Friedreich Ataxia Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Friedreich Ataxia Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Friedreich Ataxia Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Friedreich Ataxia Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Friedreich Ataxia Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Friedreich Ataxia Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Friedreich Ataxia Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Friedreich Ataxia Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Friedreich Ataxia Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Friedreich Ataxia Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Friedreich Ataxia Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Friedreich Ataxia Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Friedreich Ataxia Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Friedreich Ataxia Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Friedreich Ataxia Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Friedreich Ataxia Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Friedreich Ataxia Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Friedreich Ataxia Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Friedreich Ataxia Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Friedreich Ataxia Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Friedreich Ataxia Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Friedreich Ataxia Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Friedreich Ataxia Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Friedreich Ataxia Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Friedreich Ataxia Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Friedreich Ataxia Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Friedreich Ataxia Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Friedreich Ataxia Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Friedreich Ataxia Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Friedreich Ataxia Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Friedreich Ataxia Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Friedreich Ataxia Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Friedreich Ataxia Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Friedreich Ataxia Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Friedreich Ataxia Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Friedreich Ataxia Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Friedreich Ataxia Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Friedreich Ataxia Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Friedreich Ataxia Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Friedreich Ataxia Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Friedreich Ataxia Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Friedreich Ataxia Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Friedreich Ataxia Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Friedreich Ataxia Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Friedreich Ataxia Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Friedreich Ataxia Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Friedreich Ataxia Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Friedreich Ataxia Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Friedreich Ataxia Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Friedreich Ataxia Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Friedreich Ataxia Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Friedreich Ataxia Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Friedreich Ataxia Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Friedreich Ataxia Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Friedreich Ataxia Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Friedreich Ataxia Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Friedreich Ataxia Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Friedreich Ataxia Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Friedreich Ataxia Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Friedreich Ataxia Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Friedreich Ataxia Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Friedreich Ataxia Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Friedreich Ataxia Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Friedreich Ataxia Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Friedreich Ataxia Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Friedreich Ataxia Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Friedreich Ataxia Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Friedreich Ataxia Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Friedreich Ataxia Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Friedreich Ataxia Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Friedreich Ataxia Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Friedreich Ataxia Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Friedreich Ataxia Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Friedreich Ataxia Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Friedreich Ataxia Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Friedreich Ataxia Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Friedreich Ataxia Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Friedreich Ataxia Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Friedreich Ataxia Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Friedreich Ataxia Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Friedreich Ataxia Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Friedreich Ataxia Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Friedreich Ataxia Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Friedreich Ataxia Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Friedreich Ataxia Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Friedreich Ataxia Drug Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Friedreich Ataxia Drug Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • BVA-202
  • BHV-4157
  • AGIL-FA
  • ADVM-063
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • Takeda
  • Pfizer Inc
  • Voyager Therapeutics Inc
  • STATegics Inc
  • Retrotope Inc
  • Reata Pharmaceuticals Inc
  • RaNA Therapeutics Inc
  • ProQR Therapeutics NV
  • Ixchel Pharma LLC
  • Forward Pharma A/S
  • Catabasis Pharmaceuticals, Inc.
  • Cardero Therapeutics Inc
  • Biovista Inc.
  • BioMarin Pharmaceutical Inc.
  • Adverum Biotechnologies Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Friedreich Ataxia Drug Sales Value (2021-2032)
  4. 1.2.2 Global Friedreich Ataxia Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Friedreich Ataxia Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Friedreich Ataxia Drug Market Dynamics
  1. 2.1 Friedreich Ataxia Drug Industry Trends
  2. 2.2 Friedreich Ataxia Drug Industry Drivers
  3. 2.3 Friedreich Ataxia Drug Industry Opportunities and Challenges
  4. 2.4 Friedreich Ataxia Drug Industry Restraints
3 Friedreich Ataxia Drug Market by Company
  1. 3.1 Global Friedreich Ataxia Drug Company Revenue Ranking in 2025
  2. 3.2 Global Friedreich Ataxia Drug Revenue by Company (2021-2026)
  3. 3.3 Global Friedreich Ataxia Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Friedreich Ataxia Drug Average Price by Company (2021-2026)
  5. 3.5 Global Friedreich Ataxia Drug Company Ranking (2024-2026)
  6. 3.6 Global Friedreich Ataxia Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Friedreich Ataxia Drug Company Product Type and Application
  8. 3.8 Global Friedreich Ataxia Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Friedreich Ataxia Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Friedreich Ataxia Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Friedreich Ataxia Drug Market by Type
  1. 4.1 Friedreich Ataxia Drug Type Introduction
  2. 4.1.1 BVA-202
  3. 4.1.2 BHV-4157
  4. 4.1.3 AGIL-FA
  5. 4.1.4 ADVM-063
  6. 4.1.5 Others
  7. 4.2 Global Friedreich Ataxia Drug Sales Volume by Type
  8. 4.2.1 Global Friedreich Ataxia Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Friedreich Ataxia Drug Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Friedreich Ataxia Drug Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Friedreich Ataxia Drug Sales Value by Type
  12. 4.3.1 Global Friedreich Ataxia Drug Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Friedreich Ataxia Drug Sales Value by Type (2021-2032)
  14. 4.3.3 Global Friedreich Ataxia Drug Sales Value Share by Type (2021-2032)
5 Friedreich Ataxia Drug Market by Application
  1. 5.1 Friedreich Ataxia Drug Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Others
  5. 5.2 Global Friedreich Ataxia Drug Sales Volume by Application
  6. 5.2.1 Global Friedreich Ataxia Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Friedreich Ataxia Drug Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Friedreich Ataxia Drug Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Friedreich Ataxia Drug Sales Value by Application
  10. 5.3.1 Global Friedreich Ataxia Drug Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Friedreich Ataxia Drug Sales Value by Application (2021-2032)
  12. 5.3.3 Global Friedreich Ataxia Drug Sales Value Share by Application (2021-2032)
6 Friedreich Ataxia Drug Regional Sales and Value Analysis
  1. 6.1 Global Friedreich Ataxia Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Friedreich Ataxia Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Friedreich Ataxia Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Friedreich Ataxia Drug Sales by Region (2027-2032)
  5. 6.3 Global Friedreich Ataxia Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Friedreich Ataxia Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Friedreich Ataxia Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Friedreich Ataxia Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Friedreich Ataxia Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Friedreich Ataxia Drug Sales Value (2021-2032)
  12. 6.6.2 North America Friedreich Ataxia Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Friedreich Ataxia Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Friedreich Ataxia Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Friedreich Ataxia Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Friedreich Ataxia Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Friedreich Ataxia Drug Sales Value (2021-2032)
  21. 6.9.2 South America Friedreich Ataxia Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Friedreich Ataxia Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Friedreich Ataxia Drug Sales Value Share by Country, 2025 VS 2032
7 Friedreich Ataxia Drug Country-level Sales and Value Analysis
  1. 7.1 Global Friedreich Ataxia Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Friedreich Ataxia Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Friedreich Ataxia Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Friedreich Ataxia Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Friedreich Ataxia Drug Sales by Country (2027-2032)
  6. 7.4 Global Friedreich Ataxia Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Friedreich Ataxia Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Friedreich Ataxia Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Friedreich Ataxia Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Friedreich Ataxia Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Friedreich Ataxia Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Friedreich Ataxia Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Friedreich Ataxia Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Friedreich Ataxia Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Friedreich Ataxia Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Friedreich Ataxia Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Friedreich Ataxia Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Friedreich Ataxia Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Friedreich Ataxia Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Friedreich Ataxia Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Friedreich Ataxia Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Friedreich Ataxia Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Friedreich Ataxia Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Friedreich Ataxia Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Friedreich Ataxia Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Friedreich Ataxia Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Friedreich Ataxia Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Friedreich Ataxia Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Friedreich Ataxia Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Friedreich Ataxia Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Friedreich Ataxia Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Friedreich Ataxia Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Friedreich Ataxia Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Friedreich Ataxia Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Friedreich Ataxia Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Friedreich Ataxia Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Friedreich Ataxia Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Friedreich Ataxia Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Friedreich Ataxia Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Friedreich Ataxia Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Friedreich Ataxia Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Friedreich Ataxia Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Friedreich Ataxia Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Friedreich Ataxia Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Friedreich Ataxia Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Friedreich Ataxia Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Friedreich Ataxia Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Friedreich Ataxia Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Friedreich Ataxia Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Friedreich Ataxia Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Friedreich Ataxia Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Friedreich Ataxia Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Friedreich Ataxia Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Friedreich Ataxia Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Friedreich Ataxia Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Friedreich Ataxia Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Friedreich Ataxia Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Friedreich Ataxia Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Friedreich Ataxia Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Friedreich Ataxia Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Friedreich Ataxia Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Friedreich Ataxia Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Friedreich Ataxia Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Friedreich Ataxia Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Friedreich Ataxia Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Friedreich Ataxia Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Friedreich Ataxia Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Friedreich Ataxia Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Friedreich Ataxia Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Friedreich Ataxia Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Friedreich Ataxia Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Friedreich Ataxia Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Friedreich Ataxia Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Friedreich Ataxia Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Friedreich Ataxia Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Friedreich Ataxia Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Friedreich Ataxia Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Friedreich Ataxia Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Friedreich Ataxia Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Friedreich Ataxia Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Friedreich Ataxia Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Friedreich Ataxia Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Friedreich Ataxia Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Friedreich Ataxia Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Friedreich Ataxia Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Friedreich Ataxia Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Friedreich Ataxia Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Friedreich Ataxia Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Friedreich Ataxia Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Friedreich Ataxia Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Friedreich Ataxia Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Friedreich Ataxia Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda
  2. 8.1.1 Takeda Company Information
  3. 8.1.2 Takeda Business Overview
  4. 8.1.3 Takeda Friedreich Ataxia Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Friedreich Ataxia Drug Product Portfolio
  6. 8.1.5 Takeda Recent Developments
  7. 8.2 Pfizer Inc
  8. 8.2.1 Pfizer Inc Company Information
  9. 8.2.2 Pfizer Inc Business Overview
  10. 8.2.3 Pfizer Inc Friedreich Ataxia Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Pfizer Inc Friedreich Ataxia Drug Product Portfolio
  12. 8.2.5 Pfizer Inc Recent Developments
  13. 8.3 Voyager Therapeutics Inc
  14. 8.3.1 Voyager Therapeutics Inc Company Information
  15. 8.3.2 Voyager Therapeutics Inc Business Overview
  16. 8.3.3 Voyager Therapeutics Inc Friedreich Ataxia Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Voyager Therapeutics Inc Friedreich Ataxia Drug Product Portfolio
  18. 8.3.5 Voyager Therapeutics Inc Recent Developments
  19. 8.4 STATegics Inc
  20. 8.4.1 STATegics Inc Company Information
  21. 8.4.2 STATegics Inc Business Overview
  22. 8.4.3 STATegics Inc Friedreich Ataxia Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 STATegics Inc Friedreich Ataxia Drug Product Portfolio
  24. 8.4.5 STATegics Inc Recent Developments
  25. 8.5 Retrotope Inc
  26. 8.5.1 Retrotope Inc Company Information
  27. 8.5.2 Retrotope Inc Business Overview
  28. 8.5.3 Retrotope Inc Friedreich Ataxia Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Retrotope Inc Friedreich Ataxia Drug Product Portfolio
  30. 8.5.5 Retrotope Inc Recent Developments
  31. 8.6 Reata Pharmaceuticals Inc
  32. 8.6.1 Reata Pharmaceuticals Inc Company Information
  33. 8.6.2 Reata Pharmaceuticals Inc Business Overview
  34. 8.6.3 Reata Pharmaceuticals Inc Friedreich Ataxia Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Reata Pharmaceuticals Inc Friedreich Ataxia Drug Product Portfolio
  36. 8.6.5 Reata Pharmaceuticals Inc Recent Developments
  37. 8.7 RaNA Therapeutics Inc
  38. 8.7.1 RaNA Therapeutics Inc Company Information
  39. 8.7.2 RaNA Therapeutics Inc Business Overview
  40. 8.7.3 RaNA Therapeutics Inc Friedreich Ataxia Drug Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 RaNA Therapeutics Inc Friedreich Ataxia Drug Product Portfolio
  42. 8.7.5 RaNA Therapeutics Inc Recent Developments
  43. 8.8 ProQR Therapeutics NV
  44. 8.8.1 ProQR Therapeutics NV Company Information
  45. 8.8.2 ProQR Therapeutics NV Business Overview
  46. 8.8.3 ProQR Therapeutics NV Friedreich Ataxia Drug Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 ProQR Therapeutics NV Friedreich Ataxia Drug Product Portfolio
  48. 8.8.5 ProQR Therapeutics NV Recent Developments
  49. 8.9 Ixchel Pharma LLC
  50. 8.9.1 Ixchel Pharma LLC Company Information
  51. 8.9.2 Ixchel Pharma LLC Business Overview
  52. 8.9.3 Ixchel Pharma LLC Friedreich Ataxia Drug Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Ixchel Pharma LLC Friedreich Ataxia Drug Product Portfolio
  54. 8.9.5 Ixchel Pharma LLC Recent Developments
  55. 8.10 Forward Pharma A/S
  56. 8.10.1 Forward Pharma A/S Company Information
  57. 8.10.2 Forward Pharma A/S Business Overview
  58. 8.10.3 Forward Pharma A/S Friedreich Ataxia Drug Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Forward Pharma A/S Friedreich Ataxia Drug Product Portfolio
  60. 8.10.5 Forward Pharma A/S Recent Developments
  61. 8.11 Catabasis Pharmaceuticals, Inc.
  62. 8.11.1 Catabasis Pharmaceuticals, Inc. Company Information
  63. 8.11.2 Catabasis Pharmaceuticals, Inc. Business Overview
  64. 8.11.3 Catabasis Pharmaceuticals, Inc. Friedreich Ataxia Drug Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Catabasis Pharmaceuticals, Inc. Friedreich Ataxia Drug Product Portfolio
  66. 8.11.5 Catabasis Pharmaceuticals, Inc. Recent Developments
  67. 8.12 Cardero Therapeutics Inc
  68. 8.12.1 Cardero Therapeutics Inc Company Information
  69. 8.12.2 Cardero Therapeutics Inc Business Overview
  70. 8.12.3 Cardero Therapeutics Inc Friedreich Ataxia Drug Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Cardero Therapeutics Inc Friedreich Ataxia Drug Product Portfolio
  72. 8.12.5 Cardero Therapeutics Inc Recent Developments
  73. 8.13 Biovista Inc.
  74. 8.13.1 Biovista Inc. Company Information
  75. 8.13.2 Biovista Inc. Business Overview
  76. 8.13.3 Biovista Inc. Friedreich Ataxia Drug Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Biovista Inc. Friedreich Ataxia Drug Product Portfolio
  78. 8.13.5 Biovista Inc. Recent Developments
  79. 8.14 BioMarin Pharmaceutical Inc.
  80. 8.14.1 BioMarin Pharmaceutical Inc. Company Information
  81. 8.14.2 BioMarin Pharmaceutical Inc. Business Overview
  82. 8.14.3 BioMarin Pharmaceutical Inc. Friedreich Ataxia Drug Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 BioMarin Pharmaceutical Inc. Friedreich Ataxia Drug Product Portfolio
  84. 8.14.5 BioMarin Pharmaceutical Inc. Recent Developments
  85. 8.15 Adverum Biotechnologies Inc
  86. 8.15.1 Adverum Biotechnologies Inc Company Information
  87. 8.15.2 Adverum Biotechnologies Inc Business Overview
  88. 8.15.3 Adverum Biotechnologies Inc Friedreich Ataxia Drug Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Adverum Biotechnologies Inc Friedreich Ataxia Drug Product Portfolio
  90. 8.15.5 Adverum Biotechnologies Inc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Friedreich Ataxia Drug Value Chain Analysis
  2. 9.1.1 Friedreich Ataxia Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Friedreich Ataxia Drug Sales Mode & Process
  6. 9.2 Friedreich Ataxia Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Friedreich Ataxia Drug Distributors
  9. 9.2.3 Friedreich Ataxia Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst